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Abstract objectives To assess the prevalence and clinical importance of previously unrecognised tuberculosis
(TB) and isolation of non-tuberculous mycobacteria (NTM) among HIV-infected individuals in a
teaching hospital in Ghana.
methods Intensified mycobacterial case finding was conducted among HIV-positive individuals
before initiation of antiretroviral therapy (ART). Data were collected on socio-demographic
characteristics, medical history and TB-related signs and symptoms, and participants were followed
for six months to determine treatment and vital status. Two sputum samples were obtained and
examined for mycobacteria with smear microscopy, culture and Xpert MTB/RIF assay. NTM species
were identified with the GenoType Mycobacterium CM/AS or sequence analysis of 16S rRNA gene.
results Of 473 participants, 60 (12.7%) had confirmed pulmonary TB, and 38 (8.0%) had positive
cultures for NTM. Mycobacterium avium complex was identified in 9/38 (23.7%) of NTM isolates.
Participants with NTM isolated were more likely to have CD4 cell count< 100 cells/lL (aOR 2.37;
95% CI: 1.10-5.14), BMI<18.5kg/m2 (aOR 2.51; 95% CI: 1.15-5.51) and fever ≥2 weeks (aOR 2.76;
95% CI: 1.27-6.03) at baseline than participants with no mycobacteria. By six months, 76 (16.1%)
participants had died; 20 (33.3%) with confirmed TB and 9 (23.7%) with NTM-positive culture.
Mortality at six months was independently associated with TB diagnosis at enrolment (aHR 1.97;
95% CI 1.09-3.59), but not with NTM isolation after controlling for age, sex, CD4 cell count, BMI,
prolonged fever and ART initiation.
conclusions Intensified mycobacterial screening of HIV-infected individuals revealed a high burden
of unrecognised pulmonary TB before ART initiation, which increased risk of death within six
months. NTM were frequently isolated and associated with signs of poor clinical status but not with
increased mortality.
keywords Tuberculosis, Non-tuberculous mycobacteria, HIV, Mortality, Ghana
Introduction
Tuberculosis (TB) continues to be a leading cause of mor-
bidity and mortality among HIV-infected individuals, and
low TB case detection rates are of major concern [1]. A
recent review of autopsy studies among HIV-infected indi-
viduals found a mean TB prevalence of 43% (95% CI:
38–48) in sub-Saharan Africa with almost half of the fatal
cases undiagnosed with TB in life [2]. Intensified TB case
finding among HIV-infected individuals from South Africa
and Ethiopia revealed a high prevalence of previously
unrecognised TB at initiation of antiretroviral therapy
(ART) [3–5]. Individuals with advanced HIV disease are
also more susceptible to non-tuberculous mycobacteria
(NTM) and are at increased risk of disseminated NTM dis-
ease [6, 7]. UnlikeM. tuberculosis, NTM are ubiquitous
environmental organisms with a high diversity in
pathogenicity and clinical relevance [7]. Among NTM,
Mycobacterium avium complex (MAC) commonly causes
disseminated disease in immunocompromised HIV-
infected patients [8], and in developed countries, MAC has
been identified as an independent predictor for mortality
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[9]. Few data are available on the distribution and clinical
importance of NTM from TB endemic and HIV prevalent
settings due to inadequate laboratory capacity for
mycobacterial culture and a primary focus on TB [10]. A
study of NTM from South-East Asia found frequent NTM
isolation (21%) among newly enrolled HIV-infected indi-
viduals and presented data suggesting that NTM con-
tribute to clinical disease [11]. From sub-Saharan Africa, a
prevalence survey in Zambia found that NTM were iso-
lated in 913/6,123 (15.1%) patients considered presump-
tive TB cases [12], and NTM have previously been
associated with TB-like disease [13].
In Ghana, the overall TB incidence is 165/100 000 pop-
ulation; the TB case detection rate is estimated as low as
33% by WHO [14]. A recent study reported HIV infection
rates of up to 48% among newly diagnosed TB cases [15],
but the burden of TB among HIV-infected individuals in
Ghana is barely acknowledged. Moreover, the significance
of NTM isolation in this context is largely unknown.
In this study, we carried out intensified mycobacterial
investigations of HIV-infected individuals to assess the
prevalence of pulmonary TB and NTM isolation and fol-
lowed participants up to evaluate the clinical importance
of these pathogens.
Materials and methods
Setting and study population
This was a prospective observational study of HIV-
infected individuals enrolled between January 2013 and
March 2014 with 6 months of follow-up. The study is
based on data from a recently reported diagnostic accuracy
study of the rapid urine lipoarabinomannan (LAM) test
for TB diagnosis in Ghana [16]. In brief, the study was
conducted at the Fevers Unit, Korle-Bu Teaching Hospital
in the capital city of Accra. Fevers Unit provides HIV ser-
vices comprising voluntary counselling and testing, medi-
cal care, laboratory services, ART and adherence
counselling. As of 2014, more than 15 000 people living
with HIV (PLHIV) were enrolled at the Unit and 9028 ini-
tiated on ART (Hospital records, data unpublished).
HIV-infected adults were consecutively enrolled if
≥18 years of age and eligible for lifelong ART according
to the current programme criteria, that is a blood CD4
cell count ≤350 cells/ll, advanced HIV disease (WHO
clinical stage 3 or 4) or pregnant [17, 18]. Patients with
known TB diagnosis or who could not produce sputum
samples were excluded from the study, as were patients
treated for TB more than 2 days within the last 3 months
before enrolment. Presence of TB-related symptoms was
not used as an inclusion or exclusion criterion.
Ethics
Informed consent was obtained in writing from each par-
ticipant before enrolment. The study protocol was
approved by the Ethical and Protocol Review Committee,
University of Ghana Medical School and evaluated by the
Developing Country Committee of the Danish National
Committee on Health Research Ethics.
Data collection and laboratory investigations
A standardised questionnaire was administered to collect
data on socio-demographic characteristics and TB-rele-
vant history, signs and symptoms. We performed a basic
physical examination on all participants and obtained
blood CD4 cell count from routine services performed
prior to initiation of ART.
Participants were requested to provide one spot sputum
specimen and an early-morning specimen. Sputum sam-
ples were decontaminated and centrifuged. The pellet
was used to prepare smears that were examined micro-
scopically and graded for acid-fast bacilli using both
Ziehl–Neelsen staining method and fluorescence micro-
scopy of auramine O stained smears. The pellet was cul-
tured for mycobacteria using both solid Lowenstein-
Jensen medium and the BACTEC mycobacteria growth
indicator tube 960 system (BD Diagnostics, Sparks, MD,
USA). Sputum samples were processed at designated lab-
oratories for mycobacteria in Ghana according to stan-
dardised protocols for mycobacterial microscopy and
culture [19–21]. The Xpert MTB/RIF assay (Cepheid
Sunnyvale, CA, UDA, ‘Xpert’) became available for study
purposes in June 2013, that is after inclusion had started,
and was performed on specimens from patients included
after this date. The Xpert assay was performed on either
fresh sputum sample or on sputum sediment according to
the manufacturer’s specifications. Isolates of M. tubercu-
losis complex and NTM identified in Ghana were sent
for further speciation at the German National Reference
Centre for Mycobacteria in Borstel, a WHO-appointed
supranational reference laboratory. We used the Geno-
Type Mycobacterium CM/AS (Hain Lifescience, Nehren,
Germany) assay to identify the most common mycobacte-
ria species. Other species were identified by sequence
analysis of 16S rRNA gene.
Diagnosis and treatment
Sputum samples were transported daily to the local labo-
ratories for mycobacteria and processed within one week.
All bacteriological test results were communicated to
health staff at the Fevers Unit as soon as they became
1182 © 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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available to guide subsequent patient management. In
case of a positive test results, that is positive sputum
microscopy for acid-fast bacilli, positive culture or Xpert
result for M. tuberculosis complex, health staff contacted
the patients to begin immediate antituberculous treat-
ment. The study participants could also be initiated on
presumptive antituberculous treatment based on clinical
suspicion and positive radiological findings in accordance
with national guidelines [22]. Health staff were equally
notified in case of NTM isolation although NTM treat-
ment is not part of routine care in Ghana. However,
NTM speciation was performed after completion of the
study and hence not used to guide treatment. With the
exception of the intensified mycobacterial case finding by
the research team, other components of patient care were
at the discretion of the treating physician.
Participant outcome
All participants were followed up through review of their
routine medical records from enrolment for at least 6
months. If medical records were unavailable or if the par-
ticipant had not attended a follow-up visit as scheduled,
we contacted the participant or contact person by phone.
For all participants, we recorded the following informa-
tion: initiation date of ART, TB diagnosis subsequent to
enrolment, initiation date of TB treatment and ascer-
tained retention in programme, loss to death, loss to fol-
low-up and transfer out.
Classification and statistical methods
Participants were classified according to mycobacterial
status into one of the following three categories: ‘con-
firmed TB’, ‘NTM culture-positive’ and ‘no mycobacte-
ria’. Confirmed TB was defined as a positive culture or
Xpert result for M. tuberculosis complex in ≥1 sputum
sample. If both M. tuberculosis complex and NTM were
identified, we classified the participant as confirmed TB.
Participants were classified as NTM culture-positive when
NTM was isolated in ≥1 sputum samples. The remaining
participants were classified as having no mycobacteria.
This classification was used to enable analysis of clinical
impact of NTM isolation in patients where pulmonary
TB could be excluded. We thus assessed clinical charac-
teristics and outcomes separately for cases with confirmed
TB or with NTM-positive cultures and compared with
those of the participants classified into the no mycobacte-
ria group.
We present descriptive statistics as frequencies for cate-
gorical data and median with interquartile range (IQR)
for numeric data. Difference in variables was tested using
Wilcoxon rank-sum test, chi-square test and Fisher’s
exact tests to compare medians and proportions as
appropriate. Logistic regression was used for univariate
and multivariable analysis of risk factors’ association
with NTM isolation in sputum. Risk factors included in
analysis were age, sex, low baseline CD4 cell count
(CD4<100 cells/ll), low body mass index (BMI <18.5 kg/
m2), cough ≥2 weeks and fever ≥2 weeks.
To assess the effect of mycobacterial status at baseline
on mortality at 6 months, we used Cox proportional haz-
ard regression analysis. In addition to mycobacterial sta-
tus, we included other potential risk factors of early
mortality identified in previous studies [1]: sex, age, low
baseline CD4 cell count, low BMI, cough ≥2 weeks, fever
≥2 weeks and we adjusted for initiation of ART after
enrolment. Factors associated with mortality in univariate
analysis (P < 0.05) were included in the multivariate Cox
proportional hazard analysis retaining also age and sex.
For all factors included in the Cox model, the propor-
tional hazard assumption was validated using a test of
Schoenfeld residuals. Based on a global test value >0.05,
we implied that the model fulfilled the proportional haz-
ards assumption.
Statistical significance was defined as a two-sided
P-value <0.05, and all analyses were conducted using
STATATM version 13.1 software.
Results
Study population
We screened 571 adults, of whom 473 were eligible for
ART and able to provide 1–2 sputum samples (Figure 1).
Of the eligible participants, 304 (64.3%) were females.
Median age was 38 years (IQR 31–44.5) and median
CD4 cell count was 126 cells/ll (IQR 34–255) (Table 1).
Twenty-nine (6.1%) participants reported a prior history
of TB treatment. Smoking was not common in the study
population; only 13 (2.7%) participants were smokers at
the time and 19 (4.0%) had a history of smoking.
Prevalence of pulmonary TB and isolation of NTM
We collected 845 sputum samples; 1 sample from 101
(21.4%) participants and 2 samples from 372 (78.7%)
participants. All participants had at least one culture
result available. Xpert results were available for 195/473
(41.2%) participants.
Pulmonary TB was confirmed in 60 participants
(12.7%; 95% CI 10.0–16.0) with 12 participants having
mixed infection with NTM. NTM alone were cultured in
sputum from 38 (8.0%; 95% CI 5.9–10.9) participants.
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1183
Tropical Medicine and International Health volume 21 no 9 pp 1181–1190 september 2016
S. Bjerrum et al. TB and NTM among HIV-infected individuals in Ghana
Of these, NTM were cultured in two sputum specimens
for 7/38 (18.4%) and in a single sputum sample for the
remaining cases.
Comparative characteristics of participants across
mycobacteria status
Respiratory and non-respiratory symptoms were com-
mon, and cough ≥2 weeks was reported by 36.2% and
fever ≥2 weeks by 39.5% of participants (Table 1).
Confirmed TB cases had lower median BMI, more often
temperature ≥38 °C, increased respiration rate and
reported more symptoms than participants with no
mycobacteria (Table 1). While median CD4 cell count
was lower for TB patients than for participants with no
mycobacteria, it did not reach statistical significance.
In univariate analyses, NTM culture positivity was
associated with CD4 cell count <100 cells/ll, BMI
<18.5 kg/m2, cough ≥2 weeks or fever ≥2 (Table 2). In
the adjusted analysis, the association remained significant
for low CD4 cell count, low BMI and fever ≥2 weeks.
Laboratory investigation for mycobacteria
Of the 60 participants with confirmed TB 55 were TB
culture-positive and 5 were Xpert-positive, but TB cul-
ture-negative. Sputum smear microscopy identified TB in
32/60 (53.3%) cases. For participants with Xpert results
available and a positive culture for TB Xpert correctly
identified 27/35 (sensitivity 77.1%) of culture-confirmed
TB cases, and Xpert was specific in 155/160 (96.9%) of
culture-negative TB cases.
Two (5.3%) of the 38 participants with NTM-positive
cultures were microscopy positive, and none was
Xpert-positive. Several different NTM species were
identified, the most frequent being MAC (n = 9)
(Table 3).
Treatment status
ART was initiated for 340/473 (71.9%) participants after
a median of 14 days (IQR 7–30) from enrolment
(Table 4). TB treatment was prescribed for 39/60
(65.0%) of confirmed TB cases after a median of 14 days
571 participants
screened
498 participant
enrolled
473 eligible for
analysis
NTM culture positive
38/473 (8.0%)
No mycobacteria
375/473 (79.3%)
Confirmed TB*
60/473 (12.7%)
*Twelve paticipants had a mixed infection with TB and NTM
25 - participants
excluded
from analysis
73- not eligible
for ART
21 had no sputum
available, 4 on 
antituberculous
treatment
Figure 1 Flowchart of study participants.
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from enrolment (IQR 6–29). TB treatment was started
before ART for 34 TB cases, while 5 patients started
ART before TB treatment. Two months after enrolment,
presumptive TB treatment had been started in 39 of TB-
negative participants based on clinical presentation, x-ray
abnormalities or a positive microscopy result. Prescrip-
tion of presumptive TB treatment was more frequent in
the NTM culture-positive than the no mycobacteria
group (18.4% vs. 8.5%, P = 0.047). Of the NTM
culture-positive participants that were started on TB
treatment one participant completed treatment, three died
and three were lost to follow up (LTFU).
Participant outcomes at follow-up
By 6 months, 80/473 (16.9%) participants were LTFU
with similar rates of LTFU across mycobacterial status
(Table 4). Vital status at six months from enrolment was
Table 1 Baseline characteristics of HIV-infected individuals eligible to start ART and who were screened for mycobacteria at Korle-Bu
Teaching Hospital, Accra, Ghana
All
Confirmed
TB*
NTM culture
positive
No
mycobacteria P-value†
Participants 473 60 38 375 Confirmed TB
vs No
mycobacteria
NTM culture
positive vs
No
mycobacteria
Age, median in
years (IQR)‡
38
(31–44.5)
37 (29–43) 39 (33–45) 38 (32–45) 0.200 0.887
Sex, female 304 (64.3) 35 (58.3) 26 (68.4) 243 (64.8) 0.333 0.655
CD4, Median (IQR)‡ 126 (34–255) 93 (41–183) 47 (11–187) 136 (38–269) 0.175 0.011
CD4< 100 198 (43.3) 30 (52.6) 24 (64.9) 144 (39.7) 0.065 0.003
CD4 ≥100 259 (56.7) 27 (47.4) 13 (35.1) 219 (60.3)
BMI, median (IQR)‡ 19.8 (17.6–22.5) 17.8 (16.5–19.6) 17.9 (16.6–21.1) 20.6 (18.0–23.1) <0.001 <0.001
Physical examination
Temperature ≥38°C 47 (9.9) 22 (36.7) 3 (7.9) 22 (5.9) <0.001 0.492
Respiration rate ≥20 245 (51.8) 51 (85.0) 20 (52.6) 174 (46.4) <0.001 0.463
Lymphadenopathy 84 (17.8) 17 (28.3) 6 (15.8) 61 (16.3) <0.001 0.939
Abnormal lung sounds
(ronchie, crackles,
wheezes)
149 (31.5) 37 (61.7) 13 (34.2) 99 (26.4) <0.001 0.302
Symptoms presented
Cough ≥2 weeks 171 (36.2) 35 (58.3) 21 (55.3) 115 (30.7) <0.001 0.002
Productive cough‡ 262 (55.6) 45 (75.0) 23 (60.5) 194 (52.0) 0.001 0.316
Dyspnoea‡ 188 (40.2) 37 (62.7) 19 (50.0) 132 (35.6) <0.001 0.079
Chest pain‡ 201 (43.0) 33 (56.9) 21 (55.3) 147 (39.5) 0.013 0.060
Haemoptysis‡ 47 (10.0) 7 (11.7) 5 (13.2) 35 (9.4) 0.584 0.399
Fever ≥2 weeks 187 (39.5) 40 (66.7) 23 (60.5) 124 (33.1) <0.001 0.001
Significant weight
loss (>10%)
283 (59.8) 48 (80.0) 23 (60.5) 212 (56.5) 0.001 0.636
Night Sweats 163 (34.5) 27 (45.0) 14 (36.8) 122 (32.5) 0.059 0.590
TB History
Treated for TB 29 (6.1) 4 (6.7) 1 (2.6) 24 (6.4) 1.000 0.715
Exposure to person
known with TB
21 (4.5) 5 (8.5) 0 16 (4.3) 0.172 –
Enrolment site
In patients 72 (15.2) 17 (28.3) 7 (18.4) 48 (12.8) 0.002 0.331
Out patients 401 (84.8) 43 (71.7) 31 (81.6) 327 (87.2)
Data are presented as n (%) or median (interquartile range), unless stated otherwise.
TB, Tuberculosis; NTM, Nontuberculous mycobacteria; BMI, Body Mass Index; IQR, Interquartile Range.
*Of TB cases 12 participants had a mixed infection with NTM.
†P-values in bold indicate values less than 0.05.
‡Missing values were excluded from analysis. Of participants; 5 had missing age; 16 had missing CD4 cell count; 16 had missing
values to calculate BMI; 2 did not have information of productive cough; 5 did not have information on dyspnoea or chest pain; 3 did
not have information on haemoptysis.
© 2016 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1185
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known for 382/473 (80.8%) participants; 76 (16.1%)
had died in this group after a median of 21.5 days (IQR
10–65.5). Mortality among inpatients was 48.6% (35/72)
vs. 10.2% (41/401) among outpatients (P < 0.001). Six-
month mortality was 33.3% (20/60) among participants
with TB vs. 12.5% (47/375) among participants with no
mycobacteria. Nine (23.7%) of the participants with
NTM had died within the six months. In univariate anal-
ysis, TB diagnosis at enrolment was strongly associated
with increased risk of death at six months (HR 3.04,
95% CI 1.80–5.13) (Table 5), and this risk remained sig-
nificant after controlling for sex, age, baseline CD4, BMI,
presence of prolonged fever and initiation of ART
(Adjusted HR 1.97; 95% CI 1.09–3.59). For participants
with NTM, we saw a trend towards an increased risk of
death at six months (HR 1.85; 95% CI 0.91–3.77), but it
did not reach statistical significance in univariate analysis
and was not seen in multivariable analysis. NTM species
reported for those participants that subsequently died
were MAC (n = 2), M. chelonaecomplex (n = 2),
M. kansasii (n = 1), M. flavescens (n = 1), M. simia
(n = 1), unknown mycobacteria (n = 2).
Discussion
In this study, intensified screening for mycobacteria
revealed a substantial prevalence of unrecognised pul-
monary TB (12.7%) and frequent NTM isolation (8%)
in a population of HIV-infected individuals starting ART
at a teaching hospital in Ghana. MAC was the most com-
monly identified NTM species and severe clinical signs
and symptoms predicted NTM isolation. All-cause mor-
tality at 6 months was high (16%) in our study popula-
tion. TB diagnosis at baseline, but not NTM isolation,
was independently associated with almost doubled risk of
death.
To our knowledge, this is the first prospective study
from Ghana describing the yield of intensified TB case
finding among HIV-infected individuals. A retrospective
cohort study of PLHIV described TB as the major AIDS
defining event, but reported a quite modest event rate of
4.4% in the cohort with a median follow-up time of
30 months (IQR; 12–54) [23]. A review of intensified
TB-screening in other low- and middle-income countries
found a prevalence of confirmed TB between 6.3% and
25.7% in populations attending HIV care; the highest
Table 2 Risk factors for NTM isolation in sputum among
HIV-infected individuals based on clinical characteristics at
enrolment for individuals with NTM culture positive and no
mycobacteria
Odds ratio
(95%CI) P-value AOR* P-value‡
Age (years)†
18–34 REF REF
35–54 1.04
(0.51–2.13)
0.920 1.02
(0.47–2.21)
0.966
55– 0.69
(0.15–3.22)
0.637 0.65
(0.13–3.29)
0.603
Sex
Female REF REF
Male 0.85
(0.42–1.74)
0.656 0.74
(0.33–1.66)
0.465
CD4 count (cells/l)†
CD4 ≥100 REF
CD4 <100 2.81
(1.38–5.69)
0.004 2.37
(1.10–5.14)
0.028
BMI, (kg/m2)†
18.5–24.9 REF REF
<18.5 2.72
(1.33–5.55)
0.006 2.51
(1.15–5.51)
0.021
>25 0.68
(0.19–2.46)
0.560 1.09
(0.28–4.21)
0.898
Cough ≥2 weeks
No REF REF
Yes 2.79
(1.42–5.49)
0.003 1.67
(0.77–3.60)
0.194
Fever ≥2 weeks
No REF REF
Yes 3.10
(1.56–6.16)
0.001 2.76
(1.27–6.03)
0.011
AOR, Adjusted odds ratio; BMI, Body Mass Index.
*AOR adjusted for all variables included in table.
†Missing values were excluded from analysis. Of participan ts; 5
had missing age; 16 had missing CD4 cell count; 16 had missing
values to calculate BMI.
‡P-values in bold indicate values less than 0.05
Table 3 Identification of NTM species isolated in sputum of
HIV-infected individuals
NTM culture positive 38
M. avium complex 9 (23.7)
M. chelonae complex 3 (7.9)
M. simiae 3 (7.9)
M. fortuitum complex 2 (5.3)
M. kansasii 1 (2.6)
M. flavescens 1 (2.6)
M. terrae 1 (2.6)
M. arupense 1 (2.6)
Mycobacteria of unknown origin 6 (15.8)
Species not identified* 11 (29.0)
Data are presented as n (%). NTM, Nontuberculous
mycobacteria.
*For 11 of the NTM culture positive participants the species of
mycobacteria could not be identified; 3 isolates got contaminated
before speciation was performed, 8 isolates were unavailable for
further speciation.
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rates were found among HIV-positive patients starting
ART in South Africa [24].
In our cohort, individuals were typically initiated on
ART at advanced stage of HIV disease as indicated by
the low median CD4 cell count (126 cells/ll). This has
also been observed in other HIV cohorts from sub-
Saharan African settings [4, 5, 25] and is known to be an
important risk factor for TB and mortality among PLHIV
entering ART services [1, 26]. The high mortality in our
study population is comparable to mortality rates previ-
ously reported for other sub-Saharan African countries
within the first year after starting ART [1, 27]. We fur-
ther found that TB diagnosed upon enrolment was
strongly associated with increased mortality also after
controlling for other known risk factors for mortality,
that is age, sex, CD4 cell count and BMI at baseline. This
confirms similar findings from Uganda [28] and South
Africa [26, 29].
Intensified TB case finding in our study gave opportu-
nity to start TB treatment early, but still more than one-
third never started treatment and one-third of the TB
patients died within the first 6-month period. We did not
include any control group and will not know how inten-
sified TB case finding possibly impacted on morbidity
and mortality compared to the standard of care. How-
ever, in the context of routine care, we anticipate that far
fewer TB cases would have been identified or the TB
diagnosis delayed. Less sensitive diagnostic tools
including symptom screening followed by direct sputum
smear microscopy and chest x-ray are commonly used for
routine TB diagnosis in Ghana [15] as in other resource
limited settings [30], although the Xpert assay is becom-
ing increasingly available.
The frequent NTM isolation in our study population
was associated with characteristics of clinical disease
upon diagnosis and start of presumptive treatment for
TB. This indicates that NTM are of clinical relevance
and present with TB-like disease. The challenge is to dif-
ferentiate between NTM disease, NTM colonisation or
sample contamination. The American Thoracic Society
and the Infectious Disease Society of America provide
guidelines for the diagnosis and treatment of NTM dis-
ease that rely on three components, that is presence of
symptoms, radiological abnormalities and positive cul-
tures for NTM [6]. However, these guidelines do not
specifically target NTM disease among HIV-infected indi-
viduals and are not applicable for routine use in low-
resource settings with limited access to culture-based
diagnostics. Specific guidelines for diagnosis of MAC dis-
eases among HIV-infected are available but require labo-
ratory-intensive investigations with culture of sterile
tissue or body fluids in addition to compatible signs and
symptoms [31]. After the introduction of ART, the rate
of disseminated MAC reduced substantially in high-
income countries, although severely immunocompromised
individuals remained at risk [8]. Globally, isolation of
Table 4 Treatment status and clinical outcomes of HIV-infected individuals at 6-months after enrolment into ART services by
mycobacteria identified upon enrolment
All
Confirmed
TB
NTM culture
positive
No
mycobacteria
Participants 473 60 38 375
ART status
Started ART 340 (71.9) 42 (70) 25 (65.8) 273 (72.8)
Median time to ART (IQR)* 14 (7–30) 26 (12–42) 19 (9–39) 12 (6–25)
Tuberculosis treatment
TB treatment started 78 (16.5) 39 (65.0) 7 (18.4)†,‡ 32 (8.5)†
Median time to TB treatment (IQR) 10 (2–24) 14 (6–29) 11 (2–30) 7 (1–12)
Outcome at 6 months
Alive and retained in programme 306 (64.7) 30 (50.0) 23 (60.5) 253 (67.5)
Died 76 (16.1) 20 (33.3) 9 (23.7)§ 47 (12.5)
Lost to follow-up 80 (16.9) 9 (15.0) 6 (15.8) 65 (17.3)
Transfer out 11 (2.3) 1 (1.7) 0 10 (2.7)
Data are presented as n (%) or median (interquartile range), unless stated otherwise.
ART, Antiretroviral treatment; TB, Tuberculosis; NTM, Nontuberculous mycobacteria.
*Time to treatment defined as the time interval in days between date of inclusion and start date.
†TB treatment was started within two months of follow-up based on a positive microscopy result, clinical presentation of the partici-
pants or chest x-ray abnormalities.
‡Pairwise comparison between participants with NTM culture positive and no mycobacteria (P = 0.047).
§Pairwise comparison between participants with NTM culture positive and no mycobacteria (P = 0.056).
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NTM and NTM disease is reported more frequently [7]
and encountered with wide geographic diversity [32].
From sub-Saharan Africa, we came across studies and
case reports from Zambia [12, 33], Tanzania [13], Nige-
ria [34], and Co^te d’Ivoire [35] that confirm great varia-
tion of NTM species and a notable contribution of NTM
to TB-like disease [11, 13, 33, 34]. The most frequently
reported pathogenic species among HIV-infected include
MAC, M. kansasii and M. fortuitum [6–8] that are also
among the species identified in our study population.
Although there is no doubt that TB is the main cause of
mycobacterial disease among HIV-infected, our findings
contribute to a growing concern that the clinical impact
of NTM in TB endemic area is underestimated and that
misclassification of NTM as TB occurs [7, 10, 12, 34].
Our study was based on a rigorous strategy to identify
mycobacteria among HIV-infected individuals regardless
of presentation at enrolment. Still, we may have missed
some cases of TB as even culture and Xpert-based diag-
nosis have imperfect diagnostic sensitivity among patients
with progressive immunodeficiency [36]. We focused on
pulmonary samples that did not allow us to identify
patients presenting with only extrapulmonary TB. Fur-
thermore, our diagnosis relied on collection of sponta-
neous sputum samples from, at times, sputum-scarce
individuals. This might have compromised the diagnostic
yield of TB and NTM, but we did not find the capacity
to make use of techniques for sputum induction under
safe conditions. Excluding patients not able to produce
samples or consent due to very severe clinical status or
cerebral impairment might further have introduced a
potential selection bias as it is likely that TB dispropor-
tionally affect these patients. Another limitation is the
high rate of LTFU in our study despite of various
approaches to ascertain clinical outcomes for patients
who did not continue ART services. Although a high pro-
portion of LTFU is not unusual for this kind of study set-
ting [37], we may have underestimated mortality, as
mortality is a common cause of LTFU [38, 39]. We did
not find an association between NTM at baseline and
Table 5 Cox proportional hazards analysis for the outcome of death within 6 months based on mycobacteria status and clinical
characteristics at enrolment among HIV-infected individuals attending HIV care at Korle-Bu Teaching Hospital in Ghana
Unadjusted
HR (95%CI) P-value
Adjusted HR
(95%CI)* P-value‡
Mycobacteria status
No mycobacteria REF REF
Confirmed TB 3.04 (1.80–5.13) <0.001 1.97 (1.09–3.59) 0.026
NTM culture positive 1.85 (0.91–3.77) 0.091 0.56 (0.24–1.28) 0.168
Age (years)† 1.01 (0.98–1.03) 0.548 1.01 (0.98–1.03) 0.620
Sex
Female REF REF
Male 0.99 (0.62–1.58) 0.955 1.23 (0.73–2.08) 0.438
CD4 Cell count†
CD4 ≥100 REF REF
CD4 <100 5.55 (3.13–9.82) <0.001 6.06 (3.31–11.08) <0.001
BMI, kg/m2†
≥18.5 REF REF
<18.5 2.27 (1.44–3.56) <0.001 2.05 (1.22–3.45) 0.007
Cough ≥2 weeks
No REF – –
Yes 1.52 (0.97–32.39) 0.069 – –
Fever ≥2 weeks
No REF REF
Yes 2.25 (1.43–3.54) <0.001 1.80 (1.07–3.03) 0.028
ART status
No ART REF REF
ART initiated 0.13 (0.08–0.21) <0.001 0.08 (0.05–0.14) <0.001
ART, Antiretroviral treatment; CI, Confidence Interval; BMI, Body Mass Index; HR, Hazard Ratio; NTM, Nontuberculous mycobacte-
ria; TB, Tuberculosis;
*Hazard ratio adjusted for sex, age, and all variables significantly associated with mortality in univariate analysis (P < 0.05).
†Missing values were excluded from analysis. Of participants; 5 had missing age; 16 had missing CD4 cell count; 16 had missing
values to calculate BMI.
‡P-values in bold indicate values less than 0.05
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increased risk of death, but this is based on a limited
number of cases. Larger studies including more extensive
evaluation of the patients, consistent use of radiological
and serial diagnostic workout are required to further elu-
cidate the clinical relevance of NTM among HIV-positive
individuals and determine the prevalence of NTM disease
in patients with HIV in TB endemic settings.
Conclusion
Intensified screening for mycobacteria revealed a high
prevalence of previously unrecognised pulmonary TB and
frequent isolation of NTM among HIV-infected patients
eligible for ART in Ghana. The six-month mortality rate
was high in our study population, and TB diagnosis was
associated with increased risk of death. Isolation of NTM
was not associated with mortality at 6 months, but data
presented indicate that NTM could be of clinical rele-
vance warranting increased attention and more research.
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